Association between serum angiopoietin-2 concentrations and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention

Wen Jian1,2,3,*, Jia-Hui Guan4,*, Wen-Bo Zheng1,2,3, Chang-Hua Mo1,2,3, Yu-Tao Xu1,2,3, Qi-Li Huang1,2,3, Chun-Mei Wei1,2,3, Can Wang1,2,3, Zhi-Jie Yang1,2,3, Guo-Liang Yang1,2,3, Chun Gui1,2,3

1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People's Republic of China
2Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Nanning 530021, Guangxi, People's Republic of China
3Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, Nanning 530021, Guangxi, People's Republic of China
4Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China
*Equal contribution

Correspondence to: Chun Gui; email: guichun@yahoo.com

Keywords: angiopoietin-2, periprocedural myocardial injury, coronary artery disease, percutaneous coronary intervention, NT-proBNP

Received: October 25, 2019 Accepted: March 9, 2020 Published: March 17, 2020

Copyright: Jian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Angiopoietin-2 (Ang-2) is a proangiogenic factor that mediates inflammation and atherosclerosis. We evaluated the predictive value of circulating Ang-2 levels for periprocedural myocardial injury (PMI) in 145 patients undergoing elective percutaneous coronary intervention (PCI), and investigated whether post-PCI Ang-2 levels are influenced by PMI. PMI was defined as a post-procedural troponin elevation above the 5×99th percentile upper reference limit. Blood samples for Ang-2 analysis were collected at admission and on postoperative days 1 and 3. PMI occurred in 40 patients (28%). At baseline, there was no difference in Ang-2 levels between PMI and non-PMI patients (P=0.554). However, a significant interaction effect between PMI occurrence and time on Ang-2 levels was observed (interaction P=0.036). Although serum Ang-2 levels in non-PMI patients gradually decreased, Ang-2 levels in PMI patients did not change between different time-points. Multiple logistic regression analysis revealed that age, total stent length, and serum levels of N-terminal pro-brain natriuretic peptide were independent PMI predictors. These findings indicate that pre-procedural Ang-2 levels do not impact PMI occurrence after elective PCI. However, changes in Ang-2 levels after the procedure are closely related to PMI.

INTRODUCTION

Percutaneous coronary intervention (PCI) has become an effective and safe method for revascularization in patients with coronary artery disease (CAD), especially in an elective setting [1]. However, the high incidence of periprocedural myocardial injury (PMI) is of great concern as emerging evidence suggests a link between PMI and mortality [2–4]. PMI is frequently attributed to myocardial damage via distal embolization, side-branch occlusion, and other unexpected procedural complications. As such, PMI is most likely to occur in
patients with advanced lesions, complex anatomy, and difficult procedures [5].

Angiopoietins (Ang) are a family of growth factors that consist of four members: Ang-1, Ang-2, Ang-3, and Ang-4 [6]. Whereas Ang-1 maintains endothelial quiescence and integrity through binding the ligand of Tie2 receptor, Ang-2 acts as a context-dependent Tie2 antagonist, which inhibits the Ang-1-induced Tie2 phosphorylation, thus impairing endothelial integrity and promoting vascular leakage [7]. Ang-2 can be rapidly released from Weibel-Palade bodies of endothelial cells upon stimulation, such as hypoxia and inflammation [8, 9]. As an important proangiogenic factor, Ang-2 has been recently implicated in mediating inflammation [10–12] and atherosclerosis [13, 14]. Ang-2 is abundantly expressed in advanced human atherosclerotic lesions, and is associated with microvessel density [15, 16]. In patients with CAD, especially acute myocardial infarction (AMI), the circulating Ang-2 levels are significantly increased [17].

Previous studies have indicated an association between lesion-related risk factors and PMI [18]. The morphological characteristics of a vulnerable plaque phenotype, determined by intravascular imaging modalities, can predict the PMI occurrence [19–21]. Given the close relationship between Ang-2 levels, inflammation, and atherosclerosis, it is important to determine whether the circulating Ang-2 levels can predict the occurrence of PMI. Furthermore, previous studies have shown a significant association between mortality and circulating Ang-2 levels measured over time in multiple clinical scenarios [22–24]. We hypothesize that an increase in the circulating Ang-2 levels during hospitalization might be partly related to prominent myocardial injury, which contributes to poorer outcomes. Thus, this study aimed to evaluate the predictive value of circulating Ang-2 levels for PMI occurrence, and to investigate whether the changes in Ang-2 levels after PCI are influenced by PMI.

RESULTS

PCI patients’ characteristics

From 145 patients who underwent elective PCI, PMI occurred in 40 patients (28%). The patients’ baseline clinical characteristics are detailed in Table 1. Table 2 summarizes the angiographic and procedural characteristics. The mean age of the patients was 61 ± 10 years; 83% were men. Patients with PMI were older, and had higher serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) compared to non-PMI patients (Table 1). There was no difference in demography, medical history, medications, and baseline laboratory data between the two groups (Table 1). Figure 1 shows the post-procedural levels of high-sensitivity troponin T (hsTnT) in PMI and non-PMI patients. After PCI, hsTnT was higher in PMI patients than in non-PMI patients, while there was no significant difference in serum creatinine (Table 1). Of note, regarding to the procedural characteristics, patients with PMI had higher SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) scores, and more frequently received longer stent placements compared with non-PMI patients (Table 2).

Association between circulating Ang-2 levels and PMI

At baseline, there was no difference in Ang-2 levels between PMI and non-PMI patients (Log: 3.20 ± 0.35 vs. 3.17 ± 0.25, P=0.554; Figure 2A). However, a significant interaction effect between PMI occurrence and time on Ang-2 levels was observed (interaction P=0.036; Figure 2B). Serum Ang-2 levels in non-PMI patients gradually decreased after PCI (Log: 3.17 ± 0.25 vs. 3.12 ± 0.26 vs. 3.09 ± 0.28, P<0.001), whereas there was no change in Ang-2 levels after PCI in PMI patients (Log: 3.20 ± 0.35 vs. 3.17 ± 0.26 vs. 3.19 ± 0.26, P=0.442; Figure 2B).

Predictive factors analysis of PMI

As illustrated in Figure 3, receiver operating characteristic (ROC) curve analysis showed that NT-proBNP predicted PMI with 53% sensitivity and 74% specificity, using an optimal cutoff of 213 pg/ml (area under curve [AUC], 0.64; 95% confidence interval [CI], 0.55-0.72; P=0.011). In multivariable logistic regression analysis, age (per 10 years, odds ratio [OR]: 2.08; 95% CI: 1.25–3.48; P=0.005), total stent length (per 10 mm, OR: 1.36; 95% CI: 1.09–1.70; P=0.007), and NT-proBNP >213 pg/ml (OR: 2.63; 95% CI: 1.08–6.38; P=0.032) were independent predictors of PMI (Table 3). Combination of these 3 characteristics showed a high predictive value (AUC, 0.73; 95% CI, 0.65-0.80; P<0.001; Figure 3).

DISCUSSION

This study is the first to describe the relationship between serum Ang-2 levels and PMI occurrence in patients undergoing elective PCI. The major findings are: (1) There is no association between preoperative Ang-2 levels and PMI occurrence; (2) after PCI, the change of Ang-2 levels is closely related to PMI; and (3) NT-proBNP is an independent predictor of PMI.

In previous studies, PMI has been reported to be patient-, lesion-, and procedure-related [18]. An increase in cardiac biomarkers post procedure is very
Table 1. Patients’ characteristics.

| Demography and medical history | All patients (n=145) | PMI group (n=40) | Non-PMI group (n=105) | P-value |
|-------------------------------|----------------------|------------------|------------------------|---------|
| Age                           | 61 ± 10              | 64 ± 10          | 60 ± 9                 | 0.008   |
| BMI                           | 24.6 ± 3.6           | 24.0 ± 4.2       | 24.9 ± 3.4             | 0.170   |
| Male gender                   | 120 (83%)            | 34 (85%)         | 86 (82%)               | 0.659   |
| Smoking                       | 71 (49%)             | 18 (45%)         | 53 (50%)               | 0.555   |
| Hypertension                  | 103 (71%)            | 30 (75%)         | 73 (70%)               | 0.516   |
| Diabetes                      | 52 (36%)             | 17 (43%)         | 35 (33%)               | 0.304   |
| Renal dysfunction             | 17 (12%)             | 6 (15%)          | 11 (11%)               | 0.640   |
| Previous PCI                  | 51 (35%)             | 12 (30%)         | 39 (37%)               | 0.421   |
| Chronic heart failure         | 36 (25%)             | 13 (33%)         | 23 (22%)               | 0.187   |
| Cerebrovascular disease       | 28 (19%)             | 8 (20%)          | 20 (19%)               | 0.897   |

| Medications                   |                      |                  |                        |         |
| Statin                        | 142 (98%)            | 39 (98%)         | 103 (98%)              | 1.00    |
| Aspirin                       | 140 (97%)            | 38 (95%)         | 102 (97%)              | 0.902   |
| Clopidogrel                    | 98 (68%)             | 27 (68%)         | 71 (68%)               | 0.989   |
| Ticagrelor                     | 44 (30%)             | 13 (33%)         | 31 (30%)               | 0.728   |
| Glycoprotein IIb/IIIa inhibitor use | 23 (16%)     | 5 (13%)          | 18 (17%)               | 0.494   |

| Echocardiographic result       |                      |                  |                        |         |
| LVEF (%)                       | 66 (61–71)           | 66 (57–70)       | 66 (62–71)             | 0.438   |

| Laboratory tests at admission  |                      |                  |                        |         |
| HbA1c (%)                      | 6.2 (5.8–6.8)        | 6.2 (5.8–6.8)    | 6.2 (5.8–6.8)          | 0.712   |
| Total cholesterol (mmol/L)     | 4.3 ± 1.0            | 4.3 ± 0.8        | 4.2 ± 1.1              | 0.642   |
| LDL cholesterol (mmol/L)       | 2.3 ± 0.9            | 2.4 ± 0.8        | 2.3 ± 1.0              | 0.626   |
| WBC (x10^9/L)                  | 6.9 ± 1.8            | 6.7 ± 1.6        | 7.0 ± 1.9              | 0.401   |
| NLR                            | 2.4 ± 1.1            | 2.3 ± 1.1        | 2.4 ± 1.2              | 0.645   |
| NT-proBNP (pg/ml)              | 121 (50–423)         | 245 (69–673)     | 88 (50–271)            | 0.011   |
| Creatinine (umol/L)            | 87 ± 21              | 88 ± 23          | 86 ± 20                | 0.691   |
| hsTnT (ng/L)                   | 9 (6–12)             | 10 (6–12)        | 9 (6–11)               | 0.285   |
| Ang-2 (Log) at the baseline    | 3.18 ± 0.28          | 3.20 ± 0.35      | 3.17 ± 0.25            | 0.554   |

| Laboratory tests post-PCI      |                      |                  |                        |         |
| Creatinine (umol/L)            | 92 ± 24              | 92 ± 25          | 91 ± 24                | 0.855   |
| hsTnT (ng/L)                   | 35 (19–78)           | 135 (89–269)     | 24 (18–37)             | <0.001  |
| Ang-2 (Log) on postoperative day 1 | 3.14 ± 0.26  | 3.17 ± 0.26      | 3.12 ± 0.26            | 0.296   |
| Ang-2 (Log) on postoperative day 3 | 3.11 ± 0.28  | 3.19 ± 0.26      | 3.09 ± 0.28            | 0.051   |

Data are presented as mean ± SD, or median (IQR, interquartile range), or number (percentage). Abbreviations: Ang-2=angiopoietin-2; BMI=body mass index; BP=blood pressure; HbA1c=hemoglobin A1c; hsTnT=high sensitive troponin-T; LDL=low-density lipoprotein; LVEF=left ventricular ejection fraction; NLR=neutrophil-to-lymphocyte ratio; NT-proBNP=N-terminal pro-brain natriuretic peptide; PCI=percutaneous coronary intervention; WBC=white blood cell.
Table 2. Procedural Characteristics.

|                          | All patients (n=145) | PMI group (n=40) | Non-PMI group (n=105) | P-value |
|--------------------------|----------------------|-------------------|------------------------|---------|
| SYNTAX score             | 16 ± 10              | 19 ± 10           | 15 ± 9                 | 0.019   |
| Description of the target lesions |                      |                   |                        |         |
| Multiple vessels (two or more) | 24 (17%)       | 7 (18%)           | 17 (16%)               | 0.850   |
| LM                       | 8 (6%)               | 2 (5%)            | 6 (6%)                 | 1.000   |
| LAD                      | 74 (51%)             | 22 (55%)          | 52 (50%)               | 0.555   |
| LCx                      | 36 (25%)             | 14 (35%)          | 22 (21%)               | 0.080   |
| RCA                      | 55 (38%)             | 11 (28%)          | 44 (42%)               | 0.110   |
| CTO                      | 14 (10%)             | 5 (13%)           | 9 (9%)                 | 0.688   |
| PTCA without stenting    | 8 (6%)               | 1 (3%)            | 7 (7%)                 | 0.565   |
| Number of stents         | 1.4 ± 0.6            | 1.6 ± 0.6         | 1.3 ± 0.6              | 0.004   |
| Total stent length, mm   | 35 ± 21              | 44 ± 21           | 32 ± 20                | 0.003   |
| Pre-dilation             | 139 (96%)            | 39 (98%)          | 100 (95%)              | 0.885   |
| Post-dilation            | 127 (88%)            | 37 (93%)          | 90 (86%)               | 0.409   |
| Max balloon pressure (atm)| 17.5 ± 3.8          | 17.7 ± 3.7        | 17.4 ± 3.9             | 0.625   |
| Post-PCI TIMI-3 flow     | 144 (99%)            | 39 (98%)          | 105 (100%)             | 0.276   |

Abbreviations: CTO=chronic total occlusion; LAD=left anterior descending coronary artery; LM=left main coronary artery; LCx=left circumflex coronary artery; PTCA=percutaneous transluminal coronary angioplasty; RCA=right coronary artery; SYNTAX=Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.

Figure 1. Post-percutaneous coronary intervention troponin levels. Bars indicate median levels with interquartile range. The dotted line indicates the limit of 70 ng/L. ULN, upper limit of the normal.
common for patients undergoing PCI [25], and the incidence of PMI can vary remarkably from 5 to 33%, depending on the cardiac biomarker, marker assay, and the criteria of cut-off value [26, 27]. Notably, probably because of the use of high-sensitivity troponin assays, and the lack of effective preventive strategies [28, 29], we observed a high PMI rate of 28%. Since our study did not observe fatal or severe complications, such as acute stent thrombosis, bleeding, perforation, or stroke during the procedure, we assume that a large proportion of PMI may be attributed to the distal embolization of plaque debris.

Plaque composition, verified by multiple intravascular imaging modalities, such as optical coherence tomography [19], intravascular ultrasound [20], or near infrared spectroscopy [21], is a predominant contributor to cardiac enzyme elevation post-PCI. Several inflammatory

![Figure 2. Association between circulating Ang-2 levels and PMI.](image)

(A) Preoperative angiopoietin-2 levels (Log). (B) Angiopoietin-2 levels (Log) at different time-points (at admission, postoperative day 1 and day 3) in patients stratified by PMI. The dots indicate median levels, and bars represent interquartile range.

![Figure 3. Receiver operating characteristic curve for relevant variables predicting PMI.](image)
biomarkers have been shown to predict PMI occurrence, though the underlying mechanisms are not understood [30, 31]. We assume that the predictive value of these biomarkers for PMI may not be solely based on a direct influence of the systemic inflammatory state but reflect a parallel activation of related factors and the plaque status. Our study indicates that the pre-procedural serum Ang-2 levels do not affect the occurrence of PMI. One possible explanation is that even though Ang-2 plays a pivotal role in the inflammatory response, the circulating Ang-2 levels may not be a good biomarker reflecting the plaque status. Ang-2 expression is low in quiescent endothelium, but is upregulated following endothelial activation by stress, hypoxia, and pro-inflammatory factors [8–10]. Previous studies have demonstrated that Ang-2 is abundantly expressed locally in advanced lesions [15, 16]. However, it remains unclear whether the circulating Ang-2 levels are related to unstable plaque features, such as plaque volume, lipid core, or fibrous cap thickness. Lee et al. reported no difference in plasma Ang-2 levels between patients with unstable and stable angina [17]. Charytan et al. recently found that, in non-AMI patients, there was no significant association between serum Ang-2 levels and the total burden of coronary plaque [32]. Similar results were also described by Mitsuma et al., who found that serum Ang-2 levels were not significantly different between mild and severe CAD groups (classified by maximal percent stenosis) [33]. Given the fact that our study subjects were in a non-acute condition and scheduled for elective procedure, the relatively low circulating Ang-2 levels, which were insensitive for the discrimination of vulnerable coronary plaque, might have contributed to the negative results in this study. Since the circulating Ang-2 levels are influenced by many factors, including cardiac function [34], renal function [35], and various inflammatory conditions [11], the predictive efficiency of Ang-2 for PMI might be compromised. In addition, in this study, we used high-sensitivity troponin assays that allowed detection of a minuscule damage to myocardial tissue. Given the use of 5-fold hsTnT criteria in this study, the different cut-off values and other cardiac biomarkers, such as creatine kinase-MB, should be investigated in the future.

Importantly, our study indicates that the level of NT-proBNP, a marker reflecting pressure and volume load on the heart, is an independent predictor of PMI. This finding is consistent with a previous study which showed that the NT-pro-BNP level is a useful biomarker for predicting PMI in diabetic patients without cardiac dysfunction [36]. Although NT-proBNP is not a direct indicator of necrosis, NT-proBNP characterizes the functional state of the myocardium. Previous studies have shown that the high levels of NT-proBNP are associated with myocardial ischemia [37], and the magnitude of NT-proBNP increase after PCI correlates with the extent of myocardial injury [38]. However, we failed to provide an explanation regarding the association of preoperative NT-proBNP levels with PMI occurrence. Given the multiple clinical application values of NT-proBNP in different scenarios beyond heart failure [34, 39, 40], further large studies need to be conducted to explore and verify its precise cut-off point in predicting PMI.

Alleviation of myocardial ischemia and the effects of drugs, such as statins [41], may explain the decrease in Ang-2 levels in day 1 samples compared to the admission samples. This trend even remains in patients with PMI, although it did not reach a statistical difference. Of note, the fall in Ang-2 levels was followed by a significant increase in day 3 in PMI patients, whereas in non-PMI patients, the falling trend continued. Increased Ang-2 levels measured over time have been established as an important prognostic factor in various diseases [22–24]. We have recently found that Ang-2 levels post-PCI, but not pre-PCI, can predict the occurrence of adverse cardiovascular events [42]. However, it remained unknown whether circulating Ang-2 levels after PCI are

Table 3. Binary logistic regression model in univariate and multivariate analysis for predicting PMI.

| Predictor                        | Univariable          | Multivariable         |
|----------------------------------|----------------------|-----------------------|
| OR (95% CI)                      | P value              | OR (95% CI)           | P value |
| Age, per 10 years                | 1.75 (1.15–2.68)     | 0.010                 | 2.08 (1.25–3.48) | 0.005 |
| SYNTAX score, per 10 points      | 1.55 (1.07–2.26)     | 0.022                 | 1.12 (0.69–1.83) | 0.636 |
| Total stent length, per 10 mm    | 1.31 (1.10–1.58)     | 0.003                 | 1.36 (1.09–1.70) | 0.007 |
| NT-proBNP (>213 pg/ml)           | 3.19 (1.49–6.85)     | 0.003                 | 2.63 (1.08–6.38) | 0.032 |

Notes: The multivariate model included age, gender, hypertension, diabetes, renal dysfunction, SYNTAX score, multivessel lesion, left main artery lesion, left anterior descending artery lesion, total stent length, and NT-proBNP. CI=confidence interval; NT-proBNP=N-terminal pro-brain natriuretic peptide; OR=odds ratio; PMI=periprocedural myocardial injury; SYNTAX=Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
influenced by PMI. Therefore, this study focused on a well-characterized study population with negative troponin at admission to assess the association between Ang-2 and PMI. Intriguingly, the results are in line with our hypothesis that PMI can increase circulating Ang-2 levels. We assume that this phenomenon could be explained by microembolization. It has been previously suggested that the extent of troponin elevation after PCI correlates with a new, irreversible myocardial necrosis [43], which can induce local myocardial inflammation. Fam et al. [44] showed that Ang-2 is one of the most upregulated genes in biopsies of ischemic myocardium in patients with acute coronary syndrome. In a mouse infarct model, there was a significant gradual increase of Ang-2 expression by endothelial cells occurring at the infarct border zone, and this increase was maintained until day 7. Likewise, in a model of ischemia/reperfusion injury, Ang-2 expression began rising on day 2, but waned beginning on day 3 [45]. Therefore, the myocardial damage by microembolization due to plaque debris may increase the expression of Ang-2 in endothelial cells residing at the damaged border zone and influence its circulating levels. Thus, our data indicate that myocardial injury, reflected by increased troponin levels, is an important contributor to the elevation of circulating Ang-2 levels. This marked association can partly explain the recent evidence regarding the Ang-2 prognostic values.

An excessive and uncontrolled inflammation can exacerbate myocardial damage following PCI. Ang-2 can prime the inflammatory response, sensitize endothelial cells toward tumor necrosis factor-α, and increase expression of adhesion molecules, resulting in increased leukocyte recruitment [9]. Furthermore, Ang-2 can act as a paracrine chemoattractant promoting migration of innate immune cells by binding Tie2 receptors or in an integrin-dependent manner [12, 46, 47]. Whereas Ang-2 overexpression can facilitate the responsiveness of acute inflammation [12], Ang-2 downregulation can ameliorate post-ischemic cardiovascular remodeling after myocardial infarction, and attenuate myocardial death after ischemia/reperfusion injury [45]. Thus, the increased Ang-2 release from the heart after PCI can further aggravate the myocardial injury by amplifying cardiac hypoxia and inflammation.

Several limitations should be considered when interpreting our findings. First, this study was a single-center observational study with a relatively small sample size; thus, it is reasonable to assume that a certain amount of selection bias may exist in our study. Second, the post-procedural evidence of new myocardial ischemia, which is indispensable for the diagnosis of “type 4a myocardial infarction” [48], was not considered in this study. Third, since we collected the fasting blood samples in the morning on postoperative days 1 and 3, the extraction time was not strictly controlled. More data and large-scale studies are needed in the future.

Collectively, our findings demonstrate that the pre-procedural Ang-2 levels do not impact the PMI occurrence after elective PCI. However, the changes in Ang-2 levels after the procedure are closely related to PMI. Targeting the Ang-2 pathway may serve as a potential novel strategy for reducing the occurrence of PMI.

**MATERIALS AND METHODS**

**Study population**

The study enrolled 145 consecutive patients who underwent elective PCI with a negative hsTnT level at the time of admission, between September 2018 and September 2019. Patients were referred for numerous reasons, including atypical chest pain, stable or unstable angina, previous diagnosis of CAD in a setting of scheduled operation, or other indications for diagnostic coronary angiography. The following exclusion criteria were applied: AMI, acute heart failure, elevated hsTnT levels at admission (>99th percentile upper reference limit [URL]), unavailable measurements of serial (preprocedural and postprocedural) hsTnT, tachyarrhythmia, valvular or congenital heart disease, concomitant inflammatory conditions, end-stage renal disease, malignancies, and recent surgery or trauma (within 3 months). Medications at admission and perioperative anticoagulant therapy were chosen based on the accepted guidelines and standard methods. Dual antiplatelet treatment, including aspirin, and a P2Y12 inhibitor (chosen by the interventional cardiologist) were initiated at admission, during PCI, or immediately after PCI. Unfractionated heparin was used during the operation, and the periprocedural use of glycoprotein IIb/IIIa inhibitors was left to the operator’s discretion. Drug-eluting stents were used for patients who needed stent placement. Angiographic characteristics were recorded by experienced angiographers. The study protocol was reviewed and approved by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, China. All patients provided written informed consent.

**Related definitions**

PMI was defined based on hsTnT criteria (elevation of hsTnT above 5 x 99th percentile URL) occurring within 24 hours after the procedure suggested by the fourth universal definition [48]. Body mass index (BMI) was defined as the body mass divided by the square of the body height (kg/m²). Diabetes mellitus was defined as either a new diagnosis based on the American Diabetes
Association guidelines [49] or a history of taking antidiabetic medications. Hypertension was defined as a systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, or a history of taking antihypertensive medications. Renal dysfunction was defined as estimated glomerular filtration rate [50] <60 mL/min/1.73 m². The SYNTAX score was calculated to grade the complexity of coronary lesions [51].

Laboratory measurements

In our hospital, screening for PMI and contrast-induced nephropathy was routinely performed after the PCI. In brief, hsTnT levels were measured at admission, postoperative day 1, and when clinically indicated. Furthermore, repeated measurement of serum creatinine was conducted on postoperative day 3. Fasting blood samples for Ang-2 analysis were collected under standardized conditions at admission and on postoperative days 1 and 3. HsTnT was measured by electrochemiluminescence immunoassay (Roche Diagnostics, Risch-Rotkreuz, Switzerland) (99th percentile URL: 14 ng/L). Serum Ang-2 levels were measured using commercially available enzyme-linked immunosorbent assay kits (RayBiotech, Inc, Norcross, GA, USA). The limit of detection for Ang-2 was 10 pg/ml, with the intra-assay variability <10 % and the inter-assay variability <12 %.

Statistical analysis

Continuous variables are presented as mean ± SD or median (IQR, interquartile range), and were compared using Student t test or Mann-Whitney U test, as appropriate. Categorical variables are presented as percentage of patients; they were compared by chi-square or Fisher exact test. As the distribution of Ang-2 was skewed, a base-10 logarithmic transformation was applied. A 2-factor mixed ANOVA was used to test the interaction effect between PMI and time on Ang-2 levels after the procedure. One-way repeated-measures ANOVA test was used to analyze the Ang-2 levels over time in each group. ROC curve analysis was performed to evaluate the diagnostic value of relevant variables for PMI. Multivariable logistic regression model was constructed to assess the independent predictors of PMI, including the variables that were selected based on clinical judgement, or the known risk factors based on literature review [18], or P value < 0.05 in the univariate analysis. Ultimately, age, gender, hypertension, diabetes, renal dysfunction, SYNTAX score, multivessel lesion, left main artery lesion, left anterior descending artery lesion, total stent length, and NT-proBNP were included in the multivariate model. A 2-tailed P value < 0.05 was considered significant. Statistical analysis was performed using SPSS, version 22 and MedCalc, version 19.0.4.

Abbreviations

Ang-2: Angiopoietin-2; AMI: acute myocardial infarction; BMI: body mass index; CAD: coronary artery disease; CI: confidence interval; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-brain natriuretic peptide; OR: odds ratio; PCI: percutaneous coronary intervention; PMI: periprocedural myocardial injury; ROC: receiver operating characteristic; SYNTAX: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; URL: upper reference limit.

AUTHOR CONTRIBUTIONS

Chun Gui designed the research; Wen Jian, Jia-Hui Guan, Wen-Bo Zheng, Chang-Hua Mo, Yu-Tao Xu, Qi-Li Huang, Zhi-Jie Yang, and Guo-Liang Yang carried out the research; Wen Jian, Jia-Hui Guan, Chun-Mei Wei, and Can Wang analyzed the data; Wen Jian wrote the paper.

CONFLICTS OF INTEREST

All authors have declared that there are no conflicts of interest related to the contents of this article.

FUNDING

This study was supported by the National Natural Science Foundation of China (No. 81460063), Guangxi Natural Science Foundation (No. 2014GXNSFDA118024), and the Health Technology Research and Development Project of Guangxi (No. S2019094).

REFERENCES

1. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, et al, and Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34:2949–3003. https://doi.org/10.1093/eurheartj/eht296 PMID:23996286
2. Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le Feuvre C, Collet JP, Montalescot G, and ACTION Study Group. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018; 39:1100–09. https://doi.org/10.1093/eurheartj/ehx799 PMID:29365133
3. Thyesen K, Jaffe AS. The prognostic impact of periprocedural myocardial infarction and injury. Eur Heart J. 2018; 39:1110–12. 
   https://doi.org/10.1093/eurheartj/ehy089
   PMID: 29529182

4. Koskinas KC, Nderepepa G, Räber L, Karagiannis A, Kufner S, Zanchin T, Hieber J, Huziker L, Mayer K, Byrne RA, Heg D, Windecker S, Kastrati A. Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circ Cardiovasc Interv. 2018; 11:e006752. 
   https://doi.org/10.1161/CIRCINTERVENTIONS.118.006752
   PMID: 30545257

5. Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? Heart. 2010; 96:736–40. 
   https://doi.org/10.1136/hrt.2009.186189
   PMID: 20448123

6. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013; 328:18–26. 
   https://doi.org/10.1016/j.canlet.2012.08.018
   PMID: 22922303

7. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol. 2008; 10:527–37. 
   https://doi.org/10.1038/ncb1715
   PMID: 18425119

8. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004; 103:4150–56. 
   https://doi.org/10.1182/blood-2003-10-3685
   PMID: 14976056

9. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttrop N, Sobke A, Herrmann M, Preisner KT, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006; 12:235–39. 
   https://doi.org/10.1038/nm1351
   PMID: 16462802

10. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006; 27:552–58. 
    https://doi.org/10.1016/j.it.2006.10.004
    PMID: 17045842

11. Scholz A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci. 2015; 1347:45–51. 
    https://doi.org/10.1111/nyas.12726
    PMID: 25773744

12. Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, Drynski J, Harter PN, Mittelbronn M, Dumont DJ, Plate KH, Reiss Y. Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin-dependent manner. Blood. 2011; 118:5050–59. 
    https://doi.org/10.1182/blood-2011-03-343293
    PMID: 21868579

13. Trollope AF, Golledd J. Angiopoietins, abdominal aortic aneurysm and atherosclerosis. Atherosclerosis. 2011; 214:237–43. 
    https://doi.org/10.1016/j.atherosclerosis.2010.08.051
    PMID: 20832800

14. Theelen TL, Lappalainen JP, Sluimer JC, Gurzeler E, Cleutjens JP, Gibbels MJ, Biessen EA, Daemen MJ, Alitalo K, Ylä-Herttuala S. Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis. 2015; 241:297–304. 
    https://doi.org/10.1016/j.atherosclerosis.2015.05.018
    PMID: 26062989

15. Calvi C, Dentelli P, Pagano M, Rosso A, Pegoraro M, Giunti S, Garbarino G, Camussi G, Pegoraro L, Brizzi MF. Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced atherosclerotic plaques with high microvessel density. Arterioscler Thromb Vasc Biol. 2004; 24:511–18. 
    https://doi.org/10.1161/01.ATV.0000116891.86607.35
    PMID: 14726409

16. Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ, de Weger RA, Moll FL, Doevedans PA, Pasterkamp G, Vink A. Balance between angiopoietin 1 and angiopoietin-2 in favor of angiopoietin-1 in atherosclerotic plaques with high microvessel density. J Vasc Res. 2008; 45:244–50. 
    https://doi.org/10.1159/000112939
    PMID: 18182823

17. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 2004; 110:2355–60. 
    https://doi.org/10.1161/01.CIR.0000138112.90641.7F
    PMID: 15302795

18. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Frequency, causes, predictors, and clinical significance of periprocedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013; 34:1662–69.
19. Kini AS, Motoyama S, Vengrenyuk Y, Feig JE, Pena J, Baber U, Bhat AM, Moreno P, Kovacic JC, Narula J, Sharma SK. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015; 8:937–45. https://doi.org/10.1016/j.jcin.2015.03.016 PMID:26088511

20. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Park YA, Cho KI, Park YH, Kim DS. Meta-analysis of plaque composition by intravascular ultrasound and its relation to distal embolization after percutaneous coronary intervention. Am J Cardiol. 2013; 111:968–72. https://doi.org/10.1016/j.amjcard.2012.12.016 PMID:23351457

21. Goldstein JA, Maini B, Dixon SR, Brilakis ES, Grines CL, Rizik DG, Powers ER, Steinberg DH, Shunk KA, Weisz G, Moreno PR, Kini A, Sharma SK, et al. Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction. Circ Cardiovasc Interv. 2011; 4:429–37. https://doi.org/10.1161/CIRCINTERVENTIONS.111.963264 PMID:21972399

22. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EJ, Cook DJ, Fox-Robichaud A, Khamnoumi K, Kahn KC, Liaw PC, Liles WC. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 2011; 39:702–10. https://doi.org/10.1097/CCM.0b013e318206d285 PMID:21242795

23. Link A, Pöss J, Rbah R, Barth C, Feth L, Selejan S, Böhm M. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J. 2013; 34:1651–62. https://doi.org/10.1093/eurheartj/ehs487 PMID:23349297

24. Pöss J, Ukena C, Kindermann I, Ehrlich P, Fuernau G, Ewen S, Mahfoud F, Kriechbaum S, Böhm M, Link A. Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol. 2015; 104:380–87. https://doi.org/10.1007/s00392-014-0787-y PMID:25408112

25. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005; 26:2493–519. https://doi.org/10.1093/eurheartj/ehi455 PMID:16176941

26. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J. 2011; 32:22–31. https://doi.org/10.1093/eurheartj/ehq393 PMID:21037252

27. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med. 2011; 364:453–64. https://doi.org/10.1056/NEJMra0912134 PMID:21288097

28. Kawakita N, Ejiri K, Miyoshi T, Kohno K, Nakahama M, Doi M, Munemasa M, Murakami M, Nakamura K, Ito H, and RINC investigators. Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: secondary analysis of a randomized, controlled trial (RINC). PLoS One. 2018; 13:e0194623. https://doi.org/10.1371/journal.pone.0194623 PMID:29659585

29. Schüpke S, Hein-Rothweiler R, Mayer K, Janisch M, Sibbing D, Ndrepepa G, Hilz R, Laugwitz KL, Bernlochner I, Gschwendtner S, Kupka D, Gori T, Zeiher AM, et al, and ISAR-PLASTER-Trial Investigators. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial. Thromb Haemost. 2019; 119:1539–45. https://doi.org/10.1055/s-0039-1692423 PMID:31226721

30. Zeng RX, Li JJ, Liao PD, Zhang MZ. Relationship of non-cardiac biomarkers with periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. Int J Cardiol. 2016; 221:726–33. https://doi.org/10.1016/j.ijcard.2016.07.131 PMID:27428312

31. Jin P, Zhou Q, Song S, Xu J, Zhang M, Zhu M, Kang M, Shi X, Shi J, Lu D, Li J. Elevated preoperative HMGB1 as predictor of myocardial injury post-percutaneous coronary intervention. Medicine (Baltimore). 2016; 95:e5149. https://doi.org/10.1097/MD.0000000000005149 PMID:27861339

32. Charytan DM, Cinelli A, Zeisberg EM. Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden. Fibrogenesis Tissue Repair. 2015; 8:13. https://doi.org/10.1186/s13069-015-0029-6 PMID:26213574

33. Mitsuma W, Kodama M, Hirono S, Ito M, Ramadan MM, Tanaka K, Hoyano M, Saigawa T, Kashimura T, Fuse K, Okura Y, Aizawa Y. Angiopoietin-1, angiopoietin-2 and tie-2 in the coronary circulation of patients with and without coronary collateral vessels. Circ J. 2007; 71:343–47.
40. Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X, Feng X, Wang D, Zhang Y, Sun K, Xu B, Zhao W, Hui R, et al. Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. Eur Heart J. 2019; 40:3397–405. 
https://doi.org/10.1093/eurheartj/ehz394
PMID: 31236563

41. Hilbert T, Poth J, Frede S, Klaschik S, Hoef T, Baumgarten G, Knuefermann P. Anti-atherogenic effects of statins: impact on angiotensin-2 release from endothelial cells. Biochem Pharmacol. 2013; 86:1452–60. 
https://doi.org/10.1016/j.bcp.2013.09.004
PMID: 24041741

42. Jian W, Li L, Wei XM, Wu CQ, Gui C. Prognostic value of angiotensin-2 for patients with coronary heart disease after elective PCI. Medicine (Baltimore). 2019; 98:e14216. 
https://doi.org/10.1097/MD.0000000000014216
PMID: 30702576

43. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005; 111:1027–32. 
https://doi.org/10.1161/01.CIR.0000156328.28485.AD
PMID: 15723982

44. Fam NP, Arab S, Billia F, Han R, Proteau G, Latter D, Errett L, Bonneau D, Dunne R, Liu PP, Stewart DJ. Increased myocardial expression of angiotensin-2 in patients undergoing urgent surgical revascularization for acute coronary syndromes. Can J Cardiol. 2010; 26:365–70. 
https://doi.org/10.1016/S0828-282X(10)70417-7
PMID: 20847963

45. Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H, He Y, Kubota Y, Koh GY. Angiotensin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. J Clin Invest. 2018; 128:5018–33. 
https://doi.org/10.1172/JCI99659
PMID: 30295643

46. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scei Zonari E, Mazzieri R, Doglioni C, Naldini L. Identification of proangiogenic TIE2 expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007; 109:5276–85. 
https://doi.org/10.1182/blood-2006-10-053504
PMID: 17327411

47. Lemieux C, Maliba R, Favier J, Théorêt JF, Merhi Y, Sirois MG. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood. 2005; 105:1523–30. 
https://doi.org/10.1182/blood-2004-09-3531
PMID: 15498854

https://doi.org/10.1253/circj.71.343
PMID: 17322632

34. Jian W, Mo CH, Yang GL, Li L, Gui C. Angiopoietin-2 provides no incremental predictive value for the presence of obstructive coronary artery disease over N-terminal pro-brain natriuretic peptide. J Clin Lab Anal. 2019; 33:e22972. 
https://doi.org/10.1002/jcla.22972
PMID: 31257664

35. David S, Kümpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Böger SM, Kliem V, Haller H, Kielstein JT. Circulating angiotensin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant. 2010; 25:2571–76. 
https://doi.org/10.1093/ndt/gfn060
PMID: 2079005

36. Zeng RX, Li XL, Zhang MZ, Wang XW, Guo YL, Zhu CG, Ren Y, Li S, Zhang Y, Liu G, Xu RX, Dong Q, Li JJ. Preprocedural N-terminal pro-B-type natriuretic peptide as a useful marker for predicting periprocedural myocardial injury following percutaneous coronary intervention in diabetic patients without cardiac dysfunction. Scand J Clin Lab Invest. 2015; 75:568–77. 
https://doi.org/10.3109/00365513.2015.1060518
PMID: 26203960

37. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH, Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44:1988–95. 
https://doi.org/10.1016/j.jacc.2004.07.057
PMID: 15542281

38. Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007; 99:344–48. 
https://doi.org/10.1016/j.amjcard.2006.08.035
PMID: 17261395

39. du Fay de Lavallaz J, Badertscher P, Nestelberger T, Zimmermann T, Miró Ò, Salgado E, Christ M, Geigy N, Cullen L, Than M, Martin-Sanchez FJ, Di Somma S, Peacock WF, et al. B-Type Natriuretic Peptides and Cardiac Troponins for Diagnosis and Risk-Stratification of Syncope. Circulation. 2019. [Epub ahead of print]. 
https://doi.org/10.1161/CIRCULATIONAHA.118.038358
PMID: 30798615

40. Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X, Feng X, Wang D, Zhang Y, Sun K, Xu B, Zhao W, Hui R, et al. Implications of N-terminal pro-B-type natriuretic
48. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, and Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72:2231–64. https://doi.org/10.1016/j.jacc.2018.08.1038 PMID:30153967

49. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017 (Suppl 1); 40:S11–24. https://doi.org/10.2337/dc17-S005 PMID:27979889

50. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 PMID:19414839

51. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005; 1:219–27. PMID:19758907